vs

Side-by-side financial comparison of OCULAR THERAPEUTIX, INC (OCUL) and Ostin Technology Group Co., Ltd. (OST). Click either name above to swap in a different company.

Ostin Technology Group Co., Ltd. is the larger business by last-quarter revenue ($20.8M vs $13.3M, roughly 1.6× OCULAR THERAPEUTIX, INC). Ostin Technology Group Co., Ltd. runs the higher net margin — -24.8% vs -488.0%, a 463.1% gap on every dollar of revenue. On growth, Ostin Technology Group Co., Ltd. posted the faster year-over-year revenue change (39.2% vs -22.4%).

Ocular Therapeutix, Inc. is a biopharmaceutical firm specializing in developing and commercializing innovative ophthalmic therapies. Its products treat acute and chronic eye conditions including post-surgical pain, glaucoma, and dry eye, serving patients and ophthalmology providers primarily across the U.S. and select global markets.

Ostin Technology Group Co., Ltd. is a provider of display and interactive technology solutions. It develops and manufactures touch panels, interactive whiteboards and custom display modules, serving consumer electronics, education and commercial segments across Asia Pacific, North America and European markets.

OCUL vs OST — Head-to-Head

Bigger by revenue
OST
OST
1.6× larger
OST
$20.8M
$13.3M
OCUL
Growing faster (revenue YoY)
OST
OST
+61.6% gap
OST
39.2%
-22.4%
OCUL
Higher net margin
OST
OST
463.1% more per $
OST
-24.8%
-488.0%
OCUL

Income Statement — Q4 FY2025 vs Q2 FY2025

Metric
OCUL
OCUL
OST
OST
Revenue
$13.3M
$20.8M
Net Profit
$-64.7M
$-5.2M
Gross Margin
88.0%
9.1%
Operating Margin
-526.5%
-23.4%
Net Margin
-488.0%
-24.8%
Revenue YoY
-22.4%
39.2%
Net Profit YoY
-33.6%
-11.6%
EPS (diluted)
$-0.27
$-2.98

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
OCUL
OCUL
OST
OST
Q4 25
$13.3M
Q3 25
$14.5M
Q2 25
$13.5M
Q1 25
$10.7M
$20.8M
Q4 24
$17.1M
Q3 24
$15.4M
Q2 24
$16.4M
Q1 24
$14.8M
$15.0M
Net Profit
OCUL
OCUL
OST
OST
Q4 25
$-64.7M
Q3 25
$-69.4M
Q2 25
$-67.8M
Q1 25
$-64.1M
$-5.2M
Q4 24
$-48.4M
Q3 24
$-36.5M
Q2 24
$-43.8M
Q1 24
$-64.8M
$-4.6M
Gross Margin
OCUL
OCUL
OST
OST
Q4 25
88.0%
Q3 25
87.8%
Q2 25
85.6%
Q1 25
88.2%
9.1%
Q4 24
92.8%
Q3 24
89.9%
Q2 24
90.8%
Q1 24
91.0%
5.9%
Operating Margin
OCUL
OCUL
OST
OST
Q4 25
-526.5%
Q3 25
-472.3%
Q2 25
-502.6%
Q1 25
-597.5%
-23.4%
Q4 24
-296.1%
Q3 24
-298.2%
Q2 24
-265.1%
Q1 24
-214.0%
-25.3%
Net Margin
OCUL
OCUL
OST
OST
Q4 25
-488.0%
Q3 25
-477.3%
Q2 25
-503.9%
Q1 25
-598.7%
-24.8%
Q4 24
-283.3%
Q3 24
-236.6%
Q2 24
-266.3%
Q1 24
-438.9%
-31.0%
EPS (diluted)
OCUL
OCUL
OST
OST
Q4 25
$-0.27
Q3 25
$-0.38
Q2 25
$-0.39
Q1 25
$-0.38
$-2.98
Q4 24
$-0.25
Q3 24
$-0.22
Q2 24
$-0.26
Q1 24
$-0.49
$-0.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
OCUL
OCUL
OST
OST
Cash + ST InvestmentsLiquidity on hand
$737.1M
$1.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$654.3M
$2.7M
Total Assets
$808.1M
$52.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
OCUL
OCUL
OST
OST
Q4 25
$737.1M
Q3 25
$344.8M
Q2 25
$391.1M
Q1 25
$349.7M
$1.7M
Q4 24
$392.1M
Q3 24
$427.2M
Q2 24
$459.7M
Q1 24
$482.9M
$1.7M
Stockholders' Equity
OCUL
OCUL
OST
OST
Q4 25
$654.3M
Q3 25
$258.2M
Q2 25
$305.9M
Q1 25
$265.9M
$2.7M
Q4 24
$315.3M
Q3 24
$352.0M
Q2 24
$377.7M
Q1 24
$408.0M
$10.3M
Total Assets
OCUL
OCUL
OST
OST
Q4 25
$808.1M
Q3 25
$410.9M
Q2 25
$451.3M
Q1 25
$405.9M
$52.6M
Q4 24
$457.9M
Q3 24
$490.4M
Q2 24
$517.1M
Q1 24
$538.9M
$51.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
OCUL
OCUL
OST
OST
Operating Cash FlowLast quarter
$-54.2M
Free Cash FlowOCF − Capex
$-57.1M
FCF MarginFCF / Revenue
-430.9%
Capex IntensityCapex / Revenue
21.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-216.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
OCUL
OCUL
OST
OST
Q4 25
$-54.2M
Q3 25
$-50.7M
Q2 25
$-55.2M
Q1 25
$-44.7M
Q4 24
$-39.4M
Q3 24
$-36.6M
Q2 24
$-24.8M
Q1 24
$-33.9M
$-3.9M
Free Cash Flow
OCUL
OCUL
OST
OST
Q4 25
$-57.1M
Q3 25
$-56.7M
Q2 25
$-56.5M
Q1 25
$-46.6M
Q4 24
$-39.6M
Q3 24
$-36.6M
Q2 24
$-25.5M
Q1 24
$-34.1M
$-4.5M
FCF Margin
OCUL
OCUL
OST
OST
Q4 25
-430.9%
Q3 25
-390.0%
Q2 25
-419.7%
Q1 25
-435.6%
Q4 24
-232.0%
Q3 24
-237.6%
Q2 24
-155.4%
Q1 24
-231.1%
-30.1%
Capex Intensity
OCUL
OCUL
OST
OST
Q4 25
21.4%
Q3 25
41.2%
Q2 25
9.3%
Q1 25
18.1%
Q4 24
1.2%
Q3 24
0.6%
Q2 24
4.5%
Q1 24
1.7%
4.1%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons